DexCom (NASDAQ:DXCM) Upgraded to Buy by StockNews.com

StockNews.com upgraded shares of DexCom (NASDAQ:DXCMFree Report) from a hold rating to a buy rating in a research note released on Wednesday.

Several other brokerages have also recently issued reports on DXCM. Wells Fargo & Company lifted their target price on shares of DexCom from $110.00 to $136.00 and gave the stock an overweight rating in a report on Wednesday, December 13th. Raymond James lifted their target price on shares of DexCom from $147.00 to $151.00 and gave the stock a strong-buy rating in a report on Tuesday, January 23rd. Royal Bank of Canada assumed coverage on shares of DexCom in a report on Tuesday, March 12th. They issued an outperform rating and a $165.00 target price for the company. Finally, Piper Sandler lifted their target price on shares of DexCom from $135.00 to $150.00 and gave the stock an overweight rating in a report on Tuesday, December 19th. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $139.73.

Read Our Latest Analysis on DexCom

DexCom Trading Up 1.4 %

Shares of NASDAQ DXCM opened at $138.51 on Wednesday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. The stock has a market cap of $53.40 billion, a P/E ratio of 105.73, a price-to-earnings-growth ratio of 2.37 and a beta of 1.20. DexCom has a 1 year low of $74.75 and a 1 year high of $142.00. The firm has a 50-day moving average of $126.35 and a 200 day moving average of $113.07.

DexCom (NASDAQ:DXCMGet Free Report) last issued its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.07. The business had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The business’s revenue for the quarter was up 26.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.34 earnings per share. As a group, sell-side analysts expect that DexCom will post 1.76 EPS for the current fiscal year.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 2,902 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $123.63, for a total transaction of $358,774.26. Following the completion of the sale, the executive vice president now directly owns 79,051 shares in the company, valued at $9,773,075.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Sadie Stern sold 2,902 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $123.63, for a total transaction of $358,774.26. Following the completion of the sale, the executive vice president now directly owns 79,051 shares in the company, valued at $9,773,075.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin R. Sayer sold 37,325 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $123.63, for a total transaction of $4,614,489.75. Following the sale, the chief executive officer now owns 362,841 shares of the company’s stock, valued at $44,858,032.83. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 186,259 shares of company stock worth $24,388,086. 0.41% of the stock is owned by company insiders.

Hedge Funds Weigh In On DexCom

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in DexCom by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 44,467,463 shares of the medical device company’s stock valued at $5,517,967,000 after purchasing an additional 278,458 shares in the last quarter. Capital Research Global Investors lifted its holdings in DexCom by 21.4% during the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after purchasing an additional 2,695,296 shares in the last quarter. Sands Capital Management LLC lifted its holdings in DexCom by 10.2% during the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock valued at $1,868,647,000 after purchasing an additional 1,398,136 shares in the last quarter. Capital World Investors lifted its holdings in DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after purchasing an additional 5,256,092 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in DexCom by 2.1% during the first quarter. Geode Capital Management LLC now owns 8,282,663 shares of the medical device company’s stock valued at $960,174,000 after purchasing an additional 170,796 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

(Get Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Featured Stories

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.